WARFARIN SODIUM- warfarin sodium tablet Yhdysvallat - englanti - NLM (National Library of Medicine)

warfarin sodium- warfarin sodium tablet

unit dose services - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - warfarin sodium tablets,usp are indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets, usp have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. warfarin sodium tablets are contraindicated in: - pregnancy warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high

WARFARIN SODIUM- warfarin sodium tablet Yhdysvallat - englanti - NLM (National Library of Medicine)

warfarin sodium- warfarin sodium tablet

unit dose services - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 3 mg - warfarin sodium tablets,usp are indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets, usp have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. warfarin sodium tablets are contraindicated in: - pregnancy warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high

ATENOLOL tablet Yhdysvallat - englanti - NLM (National Library of Medicine)

atenolol tablet

contract pharmacy services-pa - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 50 mg - atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mech

CYCLOPHOSPHAMIDE tablet Yhdysvallat - englanti - NLM (National Library of Medicine)

cyclophosphamide tablet

physicians total care, inc. - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide - unii:8n3dw7272p) - cyclophosphamide 25 mg - cyclophosphamide tablets usp, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible to cyclophosphamide treatment: - malignant lymphomas (stages iii and iv of the ann arbor staging system), hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, burkitt’s lymphoma. - multiple myeloma. - leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). - mycosis fungoides (advanced disease). - neuroblastoma (disseminated disease). - adenocarcinoma of the ovary. - retinoblastoma. - carcinoma of the breast. cyclophosphamide tablets usp, 25 mg and 50 mg are useful in carefully s

APPBUTAMONE- bupropion hydrochloride, tyrosine kit Yhdysvallat - englanti - NLM (National Library of Medicine)

appbutamone- bupropion hydrochloride, tyrosine kit

physician therapeutics llc - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 75 mg - contraindications bupropion hydrochloride tablets are contraindicated in patients with a seizure disorder. bupropion hydrochloride tablets are contraindicated in patients treated with zyban (bupropion hydrochloride) sustained-release tablets; wellbutrin sr (bupropion hydrochloride), the sustained-release formulation; wellbutrin xl (bupropion hydrochloride), the extended-release formulation; or any other medications that contain bupropion because the incidence of seizure is dose dependent. bupropion hydrochloride tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in such patients treated with bupropion hydrochloride tablets. bupropion hydrochloride tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines). the concurrent administration of bupropion hydrochloride tablets and a monoamine oxidase (mao) inhibitor is contraindi

APPBUTAMONE-D- bupropion hydrochloride, tyrosine kit Yhdysvallat - englanti - NLM (National Library of Medicine)

appbutamone-d- bupropion hydrochloride, tyrosine kit

physician therapeutics llc - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 75 mg - indications and usage bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder. a physician considering bupropion hydrochloride tablets for the management of a patient’s first episode of depression should be aware that the drug may cause generalized seizures in a dose-dependent manner with an approximate incidence of 0.4% (4/1,000). this incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold. this relative risk is only an approximate estimate because no direct comparative studies have been conducted (see warnings). the efficacy of bupropion hydrochloride tablets has been established in 3 placebo-controlled trials, including 2 of approximately 3 weeks’ duration in depressed inpatients and one of approximately 6 weeks’ duration in depressed outpatients. the depressive disorder of the patients studied corresponds most closely to the major depression category of the apa diagnostic and statistical manual iii. major depression implies a promi

SEVOSOL- sevoflurane inhalant Yhdysvallat - englanti - NLM (National Library of Medicine)

sevosol- sevoflurane inhalant

vedco inc. - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane 1 ml in 1 ml - sevosol is indicated for induction and maintenance of general anesthesia in dogs. sevosol is contraindicated in dogs with a known sensitivity to sevoflurane or other halogenated agents.

A3215-18/22 REGIONAL ANESTHESIA 18G HUSTEAD/22G QUINCKE - regional anesthesia kit Yhdysvallat - englanti - NLM (National Library of Medicine)

a3215-18/22 regional anesthesia 18g hustead/22g quincke - regional anesthesia kit

smiths medical asd, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 9 mg in 1 ml - antiseptic antispetic skin preparation stop use and ask a doctor if -redness, irritation, swelling or pain persists or increases -infection occurs apply locally as needed. lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. sodium chloride injection is used to flush intravascular catheters or as a sterile, isotonic single dose vehicle, solvent, or diluent for substances to be administered intravenously, intramuscularly or sub-cutaneously and for other extemporaneously prepared single dose sterile solutio

A4109-18/27 COMBINED SPINAL/EPIDURAL 18G TUOHY/27G PENCIL POINT  - regional anesthesia kit Yhdysvallat - englanti - NLM (National Library of Medicine)

a4109-18/27 combined spinal/epidural 18g tuohy/27g pencil point - regional anesthesia kit

smiths medical asd, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - indications and usage sodium chloride injection is used to flush intravascular catheters or as a sterile, isontonic single dose vehicle, solvent, or diluent for substances to administered intravenously,k intramuscularly or sub-cutaneously and for other extemporaneously prepared single dose sterile solutions according to instructions of the manufacture of the drug to be administered. indications and usage bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings.) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of bupivacaine hydrochloride in these patients. bupivacaine hydrochloride is not recommended for intravenous regional anesthesia (bier block). (see warnings.) th

A3852-17/27 COMBINED SPINAL/EPIDURAL 17G TUOHY- regional anesthesia kit Yhdysvallat - englanti - NLM (National Library of Medicine)

a3852-17/27 combined spinal/epidural 17g tuohy- regional anesthesia kit

smiths medical asd, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - indications and usage sodium chloride injection is used to flush intravascular catheters or as a sterile, isontonic single dose vehicle, solvent, or diluent for substances to administered intravenously,k intramuscularly or sub-cutaneously and for other extemporaneously prepared single dose sterile solutions according to instructions of the manufacture of the drug to be administered. indications and usage lidocaine hydrochloride and epinephrine injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. contraindications lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. indications and usage lidocaine hydrochloride i